Literature DB >> 20962635

Disorders of phosphorus homeostasis.

Richard Lee1, Thomas J Weber.   

Abstract

PURPOSE OF REVIEW: The study of phosphorus physiology and investigations into clinical disorders of phosphorus metabolism has blossomed over the past decade. Recent work has confirmed and further extended our knowledge of basic mechanisms of phosphorus metabolism. RECENT
FINDINGS: This review will focus on FGF-23 and Klotho, and on the recent further dissection of their roles in phosphorus and skeletal metabolism. Additionally, this review will detail recent studies that implicate a role for these phosphaturic and vitamin D regulating factors in extraskeletal calcification, including that occurring in soft tissue and vascular beds.
SUMMARY: These findings in total provide fertile ground for investigations into the cause and treatment of abnormal skeletal and extraskeletal calcification in patients with inherited hypophosphatemic disorders. More importantly, and certainly with wider potential clinical application, these studies likewise imply a role for these factors in the pathogenesis of accelerated cardiovascular disease that occurs in patients with the most common hyperphosphatemic disorder, chronic kidney disease. Future studies are needed to confirm a harmful or possibly even beneficial role for FGF-23 and other factors in these disease states, and to determine whether therapeutic manipulation of these factors does truly affect clinical outcomes in patients with hypophosphatemia and hyperphosphatemia.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20962635      PMCID: PMC3740176          DOI: 10.1097/MED.0b013e32834041d4

Source DB:  PubMed          Journal:  Curr Opin Endocrinol Diabetes Obes        ISSN: 1752-296X            Impact factor:   3.243


  46 in total

1.  Therapeutic potential of klotho-FGF23 fusion polypeptides: WO2009095372.

Authors:  Mohammed S Razzaque
Journal:  Expert Opin Ther Pat       Date:  2010-07       Impact factor: 6.674

2.  Fibroblast growth factor-23 (FGF-23) is independently correlated to aortic calcification in haemodialysis patients.

Authors:  Mohamed M Nasrallah; Amal R El-Shehaby; Mona M Salem; Noha A Osman; Esam El Sheikh; Usama A A Sharaf El Din
Journal:  Nephrol Dial Transplant       Date:  2010-02-22       Impact factor: 5.992

3.  The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study.

Authors:  Benjamin D Parker; Leon J Schurgers; Vincent M Brandenburg; Robert H Christenson; Cees Vermeer; Markus Ketteler; Michael G Shlipak; Mary A Whooley; Joachim H Ix
Journal:  Ann Intern Med       Date:  2010-05-18       Impact factor: 25.391

4.  FGF23 fails to inhibit uremic parathyroid glands.

Authors:  Rocío Canalejo; Antonio Canalejo; Julio Manuel Martinez-Moreno; M Encarnacion Rodriguez-Ortiz; Jose C Estepa; Francisco Javier Mendoza; Juan Rafael Munoz-Castaneda; Victoria Shalhoub; Yolanda Almaden; Mariano Rodriguez
Journal:  J Am Soc Nephrol       Date:  2010-04-29       Impact factor: 10.121

5.  Phosphaturic action of fibroblast growth factor 23 in Npt2 null mice.

Authors:  Yuka Tomoe; Hiroko Segawa; Kazuyo Shiozawa; Ichiro Kaneko; Rieko Tominaga; Etsuyo Hanabusa; Fumito Aranami; Junya Furutani; Shoji Kuwahara; Sawako Tatsumi; Mitsutu Matsumoto; Mikiko Ito; Ken-ichi Miyamoto
Journal:  Am J Physiol Renal Physiol       Date:  2010-03-31

6.  Clinical variability of familial tumoral calcinosis caused by novel GALNT3 mutations.

Authors:  Shoji Ichikawa; Geneviève Baujat; Aksel Seyahi; Anastasia G Garoufali; Erik A Imel; Leah R Padgett; Anthony M Austin; Andrea H Sorenson; Zagorka Pejin; Vicken Topouchian; Pierre Quartier; Valerie Cormier-Daire; Michele Dechaux; Fotini Ch Malandrinou; Panagiotis N Singhellakis; Martine Le Merrer; Michael J Econs
Journal:  Am J Med Genet A       Date:  2010-04       Impact factor: 2.802

7.  Treatment of X-linked hypophosphatemia with calcitriol and phosphate increases circulating fibroblast growth factor 23 concentrations.

Authors:  Erik A Imel; Linda A DiMeglio; Siu L Hui; Thomas O Carpenter; Michael J Econs
Journal:  J Clin Endocrinol Metab       Date:  2010-02-15       Impact factor: 5.958

8.  Autosomal-recessive hypophosphatemic rickets is associated with an inactivation mutation in the ENPP1 gene.

Authors:  Varda Levy-Litan; Eli Hershkovitz; Luba Avizov; Neta Leventhal; Dani Bercovich; Vered Chalifa-Caspi; Esther Manor; Sophia Buriakovsky; Yair Hadad; James Goding; Ruti Parvari
Journal:  Am J Hum Genet       Date:  2010-02-04       Impact factor: 11.025

9.  Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD.

Authors:  James B Wetmore; Shiguang Liu; Ron Krebill; Rochelle Menard; L Darryl Quarles
Journal:  Clin J Am Soc Nephrol       Date:  2009-11-05       Impact factor: 8.237

10.  Common genetic variants associate with serum phosphorus concentration.

Authors:  Bryan Kestenbaum; Nicole L Glazer; Anna Köttgen; Janine F Felix; Shih-Jen Hwang; Yongmei Liu; Kurt Lohman; Stephen B Kritchevsky; Dorothy B Hausman; Ann-Kristin Petersen; Christian Gieger; Janina S Ried; Thomas Meitinger; Tim M Strom; H Erich Wichmann; Harry Campbell; Caroline Hayward; Igor Rudan; Ian H de Boer; Bruce M Psaty; Kenneth M Rice; Yii-Der Ida Chen; Man Li; Dan E Arking; Eric Boerwinkle; Josef Coresh; Qiong Yang; Daniel Levy; Frank J A van Rooij; Abbas Dehghan; Fernando Rivadeneira; André G Uitterlinden; Albert Hofman; Cornelia M van Duijn; Michael G Shlipak; W H Linda Kao; Jacqueline C M Witteman; David S Siscovick; Caroline S Fox
Journal:  J Am Soc Nephrol       Date:  2010-06-17       Impact factor: 10.121

View more
  1 in total

1.  Examining the association between serum phosphate levels and leukocyte telomere length.

Authors:  Zhe-Yu Yang; Tung-Wei Kao; Tao-Chun Peng; Yuan-Yuei Chen; Hui-Fang Yang; Chen-Jung Wu; Wei-Liang Chen
Journal:  Sci Rep       Date:  2020-03-25       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.